Bristol-Myers Squibb (BMY) Stock: Charts & Financials

Bristol-Myers Squibb Company (BMY)BMYBristol-Myers Squibb Company

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ

32,500 employees

www.bms.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher S. Boerner

View full financials

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Total Current Assets	27.21B	27.21B	29.39B	35.63B	33.22B	30.78B	29.78B	28.07B	26.89B
Cash & Cash Equivalents	9.57B	9.57B	10.21B	15.73B	12.60B	10.88B	10.35B	7.89B	6.29B
Short-Term Investments	912.00M	912.00M	464.00M	776.00M	1.00B	907.00M	513.00M	204.00M	360.00M
Cash & Short-Term Investments	10.49B	10.49B	10.67B	16.50B	13.60B	11.78B	10.86B	8.09B	6.65B
Accounts Receivable	12.08B	12.08B	14.53B	14.62B	15.10B	14.59B	14.42B	14.89B	15.15B
Inventory	2.76B	2.76B	2.69B	2.76B	2.74B	2.67B	2.56B	3.33B	3.08B
Total Assets	86.48B	86.48B	90.04B	96.89B	94.68B	92.43B	92.60B	93.67B	94.65B
Property, Plant & Equipment	9.19B	9.19B	9.13B	7.35B	8.65B	8.43B	8.36B	8.25B	8.16B
Goodwill	21.74B	21.74B	21.75B	21.75B	21.78B	21.74B	21.72B	21.75B	21.73B
Intangible Assets	18.49B	18.49B	19.35B	20.46B	21.66B	22.80B	23.64B	27.33B	29.84B
Long-Term Investments	2.24B	2.24B	2.51B	2.36B	2.25B	2.25B	2.51B	2.85B	3.00B
Total Current Liabilities	19.16B	19.16B	23.42B	28.14B	27.53B	24.07B	23.77B	22.64B	23.27B
Accounts Payable	4.23B	4.23B	3.58B	4.29B	5.43B	4.00B	3.60B	3.47B	3.75B
Short-Term Debt	2.31B	2.31B	2.26B	4.51B	4.71B	3.55B	2.05B	1.08B	3.53B
Total Liabilities	66.37B	66.37B	71.53B	78.29B	77.19B	74.98B	76.22B	76.47B	77.58B
Long-Term Debt	42.15B	42.15B	42.85B	44.47B	44.47B	46.16B	47.60B	48.67B	48.86B
Total Debt	44.46B	44.46B	47.14B	51.04B	50.93B	51.24B	51.20B	51.40B	54.00B
Net Debt (Cash)	34.89B	34.89B	36.93B	35.31B	38.33B	40.36B	40.85B	43.51B	47.71B
Total Shareholders' Equity	20.07B	20.07B	18.47B	18.55B	17.43B	17.39B	16.34B	17.14B	17.02B
Common Stock	292.00M	292.00M	292.00M	292.00M	292.00M	292.00M	292.00M	292.00M	292.00M
Retained Earnings	18.29B	18.29B	16.90B	17.09B	16.15B	16.11B	14.91B	16.10B	16.10B
Current Ratio	1.42	1.42	1.26	1.27	1.21	1.28	1.25	1.24	1.16
Debt to Equity Ratio	2.22	2.22	2.55	2.75	2.92	2.95	3.13	3.00	3.17

Quarterly Report

TTM

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Quarter ended Jun 2024

Total Current Assets

27.21B

29.39B

35.63B

33.22B

30.78B

29.78B

28.07B

26.89B

Cash & Cash Equivalents

9.57B

10.21B

15.73B

12.60B

10.88B

10.35B

7.89B

6.29B

Short-Term Investments

912.00M

464.00M

776.00M

1.00B

907.00M

513.00M

204.00M

360.00M

Cash & Short-Term Investments

10.49B

10.67B

16.50B

13.60B

11.78B

10.86B

8.09B

6.65B

Accounts Receivable

12.08B

14.53B

14.62B

15.10B

14.59B

14.42B

14.89B

15.15B

Inventory

2.76B

2.69B

2.76B

2.74B

2.67B

2.56B

3.33B

3.08B

Total Assets

86.48B

90.04B

96.89B

94.68B

92.43B

92.60B

93.67B

94.65B

Property, Plant & Equipment

9.19B

9.13B

7.35B

8.65B

8.43B

8.36B

8.25B

8.16B

Goodwill

21.74B

21.75B

21.78B

21.74B

21.72B

21.75B

21.73B

Intangible Assets

18.49B

19.35B

20.46B

21.66B

22.80B

23.64B

27.33B

29.84B

Long-Term Investments

2.24B

2.51B

2.36B

2.25B

2.51B

2.85B

3.00B

Total Current Liabilities

19.16B

23.42B

28.14B

27.53B

24.07B

23.77B

22.64B

23.27B

Accounts Payable

4.23B

3.58B

4.29B

5.43B

4.00B

3.60B

3.47B

3.75B

Short-Term Debt

2.31B

2.26B

4.51B

4.71B

3.55B

2.05B

1.08B

3.53B

Total Liabilities

66.37B

71.53B

78.29B

77.19B

74.98B

76.22B

76.47B

77.58B

Long-Term Debt

42.15B

42.85B

44.47B

46.16B

47.60B

48.67B

48.86B

Total Debt

44.46B

47.14B

51.04B

50.93B

51.24B

51.20B

51.40B

54.00B

Net Debt (Cash)

34.89B

36.93B

35.31B

38.33B

40.36B

40.85B

43.51B

47.71B

Total Shareholders' Equity

20.07B

18.47B

18.55B

17.43B

17.39B

16.34B

17.14B

17.02B

Common Stock

292.00M

Retained Earnings

18.29B

16.90B

17.09B

16.15B

16.11B

14.91B

16.10B

Current Ratio

1.42

1.26

1.27

1.21

1.28

1.25

1.24

1.16

Debt to Equity Ratio

2.22

2.55

2.75

2.92

2.95

3.13

3.00

3.17

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Current Assets	29.39B	29.78B	31.77B	27.27B	33.26B	30.19B	29.35B	17.72B
Cash & Cash Equivalents	10.21B	10.35B	11.46B	9.12B	13.98B	14.55B	12.35B	6.91B
Short-Term Investments	464.00M	513.00M	816.00M	130.00M	3.24B	1.90B	3.05B	1.85B
Cash & Short-Term Investments	10.67B	10.86B	12.28B	9.25B	17.22B	16.45B	15.39B	8.76B
Accounts Receivable	14.53B	14.42B	15.26B	13.94B	12.52B	10.55B	7.68B	5.75B
Inventory	2.69B	2.56B	2.66B	2.34B	2.10B	2.07B	4.29B	1.20B
Total Assets	90.04B	92.60B	95.16B	96.82B	109.31B	118.48B	129.94B	34.99B
Property, Plant & Equipment	9.13B	8.36B	8.04B	7.47B	6.97B	6.75B	6.96B	5.03B
Goodwill	21.75B	21.72B	21.17B	21.15B	20.50B	20.55B	22.49B	6.54B
Intangible Assets	19.10B	23.64B	27.48B	36.35B	42.77B	53.45B	63.97B	1.09B
Long-Term Investments	2.51B	2.51B	2.50B	2.19B	2.71B	4.51B	4.17B	1.77B
Total Current Liabilities	23.42B	23.77B	22.26B	21.89B	21.87B	19.08B	18.30B	10.65B
Accounts Payable	3.58B	3.60B	3.26B	3.04B	2.95B	2.71B	2.44B	1.89B
Short-Term Debt	2.26B	2.05B	3.12B	4.26B	4.95B	2.34B	3.35B	1.70B
Total Liabilities	71.53B	76.22B	65.67B	65.70B	73.31B	80.60B	78.25B	20.86B
Long-Term Debt	42.85B	47.60B	36.65B	35.06B	39.60B	48.34B	43.39B	5.65B
Total Debt	47.14B	51.20B	41.46B	40.72B	45.60B	51.67B	47.54B	7.35B
Net Debt (Cash)	36.93B	40.85B	30.00B	31.59B	31.62B	37.13B	35.19B	438.00M
Total Shareholders' Equity	18.47B	16.34B	29.43B	31.06B	35.95B	37.82B	51.60B	14.03B
Common Stock	292.00M	292.00M	292.00M	292.00M	292.00M	292.00M	292.00M	221.00M
Retained Earnings	16.90B	14.91B	28.77B	25.50B	23.82B	21.28B	34.47B	34.06B
Current Ratio	1.26	1.25	1.43	1.25	1.52	1.58	1.60	1.66
Debt to Equity Ratio	2.55	3.13	1.41	1.31	1.27	1.37	0.92	0.52

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Total Current Assets

29.39B

29.78B

31.77B

27.27B

33.26B

30.19B

29.35B

17.72B

Cash & Cash Equivalents

10.21B

10.35B

11.46B

9.12B

13.98B

14.55B

12.35B

6.91B

Short-Term Investments

464.00M

513.00M

816.00M

130.00M

3.24B

1.90B

3.05B

1.85B

Cash & Short-Term Investments

10.67B

10.86B

12.28B

9.25B

17.22B

16.45B

15.39B

8.76B

Accounts Receivable

14.53B

14.42B

15.26B

13.94B

12.52B

10.55B

7.68B

5.75B

Inventory

2.69B

2.56B

2.66B

2.34B

2.10B

2.07B

4.29B

1.20B

Total Assets

90.04B

92.60B

95.16B

96.82B

109.31B

118.48B

129.94B

34.99B

Property, Plant & Equipment

9.13B

8.36B

8.04B

7.47B

6.97B

6.75B

6.96B

5.03B

Goodwill

21.75B

21.72B

21.17B

21.15B

20.50B

20.55B

22.49B

6.54B

Intangible Assets

19.10B

23.64B

27.48B

36.35B

42.77B

53.45B

63.97B

1.09B

Long-Term Investments

2.51B

2.50B

2.19B

2.71B

4.51B

4.17B

1.77B

Total Current Liabilities

23.42B

23.77B

22.26B

21.89B

21.87B

19.08B

18.30B

10.65B

Accounts Payable

3.58B

3.60B

3.26B

3.04B

2.95B

2.71B

2.44B

1.89B

Short-Term Debt

2.26B

2.05B

3.12B

4.26B

4.95B

2.34B

3.35B

1.70B

Total Liabilities

71.53B

76.22B

65.67B

65.70B

73.31B

80.60B

78.25B

20.86B

Long-Term Debt

42.85B

47.60B

36.65B

35.06B

39.60B

48.34B

43.39B

5.65B

Total Debt

47.14B

51.20B

41.46B

40.72B

45.60B

51.67B

47.54B

7.35B

Net Debt (Cash)

36.93B

40.85B

30.00B

31.59B

31.62B

37.13B

35.19B

438.00M

Total Shareholders' Equity

18.47B

16.34B

29.43B

31.06B

35.95B

37.82B

51.60B

14.03B

Common Stock

292.00M

221.00M

Retained Earnings

16.90B

14.91B

28.77B

25.50B

23.82B

21.28B

34.47B

34.06B

Current Ratio

1.26

1.25

1.43

1.25

1.52

1.58

1.60

1.66

Debt to Equity Ratio

2.55

3.13

1.41

1.31

1.27

1.37

0.92

0.52

Balance Sheet

Quarterly Balance Sheet (USD)

Annual Balance Sheet (USD)